CAPNet-network of competence for Community Acquired Pneumonia: Structures and aims;CAPNetz-kompetenznetzwerk ambulant erworbene pneumonie: Strukturen und ziele

Pneumologie

Volumn 57, Issue 1, 2003, Pages 34-41

  Welte, T ^a,b   Marre, R ^a   Suttorp, N ^a  

^a CAPNetz Geschäftsstelle   (Germany)

^b Geschäftsstelle CAPNetz ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MACROLIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; CLINICAL FEATURE; GERMANY; HEALTH CARE COST; HEALTH SERVICE; HUMAN; INCIDENCE; MEDICAL RESEARCH; MORTALITY; PNEUMONIA; PRIORITY JOURNAL; REVIEW; SYMPTOMATOLOGY; THORAX RADIOGRAPHY;

COMMUNITY-ACQUIRED INFECTIONS; GEOGRAPHY; GERMANY; HUMANS; INCIDENCE; PNEUMONIA; SOFTWARE;

EID: 0037280160     PISSN: 09348387     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-36635     Document Type: Review

References (22)

1. Osler W. Lobar pneumonia. In: The principles and practice of of medicine. Edinburgh & London: Young J, Pentland, 1901; 126-129
2. Chanock RM, Dienes L, Eaton MD. Mycoplasma pneumoniae: proposed nomenclature for atypical pneumonia organism. Science 1963; 140: 662-669
3. Farr BM, Kaiser DL, Harrison BDW et al. Prediction of microbial aetiology at admission to hospital for pneumonia from the presenting clinical features. Thorax 1989; 44: 1031-1035
4. Tew J, Calenoff L, Berlin BS. Bacterial or nonbacterial pneumonia: accuracy of radiographic diagnosis. Radiology 1977; 124: 607-612
5. Woodhead M, Torres A. Definition and classification of community-acquired and nosocomial pneumonias. Eur Respir Mon 1997; 3: 1-12
6. Escamilla R, Hermant C. Pneumonia in immunocompromised patients. Eur Respir Mon 1997; 3: 189-208
7. Pingleton SK, Fagon JY, Leeper KV. Patient selection for clinical investigation of ventilator-associated pneumonia. Chest 1992; 102 (Suppl. 1): 557S-564S
8. ERS Task Force Report. Guidelines for management of adult community-acquired lower respiratory tract infections. Eur Respir J 1998; 11: 986-991
9. Bartlett JG, Breiman RF, Mandell LA et al. Community-acquired pneumonia in adults: Guidelines for management. Clin Infect Dis 1998; 26: 811-838
10. Lopez AD, Murray CC. The global burden of disease. Nat Med 1998; 4: 1241-1243
11. Center for Disease Control and Prevention. Premature deaths, monthly mortality and monthly physician contacts - United States. MMWR Morb Mortal Wkly Rep 1997; 46: 556
12. Marston BJ, Plouffe JF, File TM et al. Incidence of community acquired pneumonia requiring hospitalizations. Arch Intern Med 1997; 157: 1509-1518
13. Niederman MS, McCombs JS, Unger AN et al. The cost of treating community-acquired pneumonia. Clin Ther 1998; 20: 820-837
14. Fine MJ, Auble TE, Yealy DM et al. A prediction rule to identify low-risk patients with community acquired pneumonia. N Engl J Med 1997; 336: 243-250
15. Marrie TJ, Lau CY, Wheeler SL et al. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. JAMA 2000; 283: 749-755
16. Fine MJ, Smith MA, Carson CA et al. Prognosis and outcome of patients with community acquired pneumonia. JAMA 1996; 275: 134-141
17. Dean NC, Silver MP, Bateman KA et al. Decreased mortality after implementation of a treatment guideline for community-acquired pneumonia. Am J Med 2001; 110: 451-457
18. Moroney JF, Fiore AE, Harrison LH et al. Clinical outcomes of bacteremic pneumococcal pneumonia in the era of antibiotic resistance. Clin Infect Dis 2001; 33: 797-805
19. Reinert RR, Al-Lahham A, Lemperle M et al. Emergence of macrolide and penicillin resistance among invasive pneumococcal isolates in Germany. J Antimicrob Chemother 2002; 49: 61-68
20. Priest P, Yudkin P, McNulty C. Antibacterial prescribing and antibacterial resistance in English general practice: cross sectional study. BMJ 2001; 323: 1037-1041
21. Ross JJ, Worthington MG, Gorbach SL. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002; 347: 65-67
22. Marrie TJ, Peeling RW, Fine MJ. Ambulatory patients with community acquired pneumonia, the frequency of atypical agents and clinical course. Am J Med 1996; 101: 508-515